MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing advanced therapies for serious inflammatory diseases. Focused on addressing significant unmet medical needs, MoonLake specializes in targeting specific interleukins, particularly IL17A and IL17F, which are known to play critical roles in conditions such as psoriasis, hidradenitis suppurativa, psoriatic arthritis, and ankylosing spondylitis. The company's flagship product, Sonelokimab, is undergoing extensive clinical trials and is designed to improve treatment outcomes for patients suffering from these debilitating disorders.

Led by founder and CEO Jorge Santos da Silva, MoonLake is committed to innovative research and the application of cutting-edge science. The company actively participates in global clinical trials, aiming to transform patient care through its promising therapies. With a focus on strategic investor relations and a proactive approach to corporate governance, MoonLake Immunotherapeutics is dedicated to advancing the future of treatment for inflammatory diseases and enhancing the quality of life for patients worldwide.